Illumina next-generation sequencing (NGS) and microarray technologies represent the gold standard in quality worldwide—and account for ~90% of the world’s sequencing data.* Innovative, intuitive, and completely integrated, our sample-to-data solutions empower your lab to keep ahead of the curve in the rapidly evolving genomics revolution. So you’ll be better able to perform the world-class cancer genomics research you strive for—with the goal of uncovering new insights into the biology of cancer that can lead to meaningful advances in personalized medicine.
Our comprehensive genomics product offerings support multiple cancer research applications, including studies of DNA, RNA, epigenetics, and more. Our range of sequencers can be scaled to meet your needs—from powerful, yet personal, benchtop models to versatile, high-throughput systems. With intuitive data analysis and management capabilities and unsurpassed customer support, we can deliver the answers you seek—quickly, accurately, and cost-effectively.
Explore genomics-based approaches to investigating cancer using NGS and microarrays.
During this webinar, our expert speakers provide background information on next-generation sequencing (NGS), discuss the achievements and challenges associated with NGS, and discuss how an integrated multiomics approach can be used in cancer diagnosis and treatment.View Webinar
AJ Patel had six months to live. Eight years later, he tells us how biomarker testing changed everything.Read Article
Whole-exome sequencing on formalin-fixed, paraffin-embedded tumor tissue with Illumina DNA Prep with EnrichmentRead Interview
San Diego-based molecular diagnostics company PetDx wants to help your four-legged friendRead Article
Unify single-cell gene expression and chromatin accessibility to help reveal cellular mechanisms driving gene regulation.Read Tech Note
Learn how to incorporate protein detection into bulk RNA-Seq and develop a workflow for BEN-Seq, providing a holistic approach to cell analysis.Read Application Note
In this podcast episode, Drs. Obi and Malachi Griffith, Professors of Medicine at Washington University in St. Louis, MO, discuss their work in improving interpretations of sequence variants in cancer and enhancing bioinformatics education.Listen Now
*Data on file based on a 2013 study.